Ovid Therapeutics : November Corporate Deck

Published: 2024-11-12 08:51:11 ET OVID

Ovid Therapeutics

Corporate Presentation

November 2024

Forward looking statement

This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 including, without limitation, the potential therapeutic benefits of Ovid's current or future product candidates and pipeline programs; Ovid's expectations regarding the duration its cash runway, and the expectation that it will support the advancement of Ovid's pipeline; statements regarding the expected timing of the initiation, completion, and results and data of Ovid's clinical studies; the potential to add additional cohorts to the Phase 1 MAD study of OV329, expected timing of completion of the study and expected timing of data presentation; the expected timing of submission of a regulatory application for

a Phase 1 trial of OV350 IV and, the expected timing of initiation of the trial and expected timing of data presentation; Ovid's evaluation of the results of recently completed competitor trials to OV888/GV101 for CCM; the potential use and development of OV329, OV350 and other compounds from Ovid's library of direct activators of KCC2, and OV888/GV101 and other ROCK2 inhibitors; the potential therapeutic opportunity of OV329, OV350 and other compounds from Ovid's library of direct activators of KCC2, and OV888/GV101 and other ROCK2 inhibitors; the potential use of OV329 to treat neuronal hyperexcitability; the likelihood that data, including safety and tolerability data, for OV329 will support future development and therapeutic potential; the suitability of OV329 for a range indication opportunities; the clinical and regulatory development of KCC2 compounds in the Company's library including OV350, OV4071, OV4000 series and OV5000 series; the suitability of the Company's library of novel, direct KCC2 transporter activators for a range of formulations and administrations; the potential development and therapeutic opportunity of OV888/GV101; and the potential safety, selectivity and potency of OV888/GV101 and other ROCK2 inhibitors; and expectations regarding the size of the market for Ovid's current or future product candidates and pipeline programs. You can identify forward-looking statements because they contain words such as "will," "may," "plan," "believes," "intends," "anticipates," "design," "advance," "target," "seek," "expects," "demonstrates," and "potential," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances).

Forward-looking statements are based on Ovid's current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical factor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, uncertainties inherent in the preclinical and clinical development and regulatory approval processes, risks related to Ovid's ability to achieve its financial objectives, the risk that Ovid may not be able to realize the intended benefits of its technology or its business strategy, risks related to Ovid's ability to identify business development targets or strategic partners, to enter into strategic transactions on favorable terms, or to consummate and realize the benefits of any business development transactions and risks to Ovid's or any of its partners' abilities to meet anticipated deadlines and milestones. Additional risks that could cause actual results to differ materially from those in the forward-looking statements are set forth under the caption "Risk Factors" in Ovid's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on November 12, 2024, and in future filings Ovid makes with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Ovid assumes no obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

OUR FOCUS

Foundational biological targets

Implicated in neuronal hyperexcitability, neuroinflammation or neurovascular dysfunction

Highly specific small molecules

Harnessing a scientific revolution in mechanistically targeted small molecules for the central nervous system

Substantial therapeutic opportunities

across neurological and neuropsychiatric conditions with deep unmet need

Cash balance of $62.7 million

expected to support pipeline to H2 20261

1. As of September 30, 2024

OUR SCIENCE

Unique mechanisms with broad

therapeutic potential

Proven developers

OV329, a next generation

of candidates to mitigate

GABA-aminotransferase inhibitor

neuronal hyperexcitability

Pioneers of KCC2

OV350, OV4071 & portfolio of

direct activation

direct activators

Translators of ROCK2

OV888/GV101, a highly selective

inhibition in the brain

ROCK2 inhibitor

Differentiated pipeline, advancing in the clinic

Programs

Indication

Preclinical Phase 1 Phase 2 Phase 3

Anticipated Milestones

OV329

• Conditions with

Phase 1 estimated readout in 2025

GABA-aminotransferase

neuronal

Topline timing to be updated following discussions

hyperexcitability

with regulators

inhibitor

OV350 & KCC2

• Neuropsychiatric

LIBRARY

• Neurodevelopmental

KCC2 direct activator

• Neurodegenerative

Phase 1 initiation expected in Q1 2025

• Seizures

OV888/GV1011

• Cerebral cavernous

Pausing initiation of Phase 2 program in

malformations

CCM to evaluate insights from recently

Selective ROCK2 inhibitor

• Undisclosed

completed competitor programs

Collaboration with:

neurovascular

OV888/GV101 intravenous formulation

indications

in preclinical development

1. Graviton is conducting development of OV888/GV101 capsule through Phase 2, which will be directed by a Joint Development Committee that includes members from both Graviton and Ovid.

Third quarter corporate updates

Presented OV329 head-to-head preclinical ocular results

Pipeline actions

Extended cash runway to H2 20261

1. As of September30,2024

Anticipated pipeline milestones

Program

Key milestones

Anticipated Timing

OV329

Results of Phase 1 SAD/ MAD with MRS and

2025

TMS biomarkers

Detailed timeline for topline and Phase 2 to be

provided following discussions with regulators

Regulatory submission for first-in-human study of

Q4 2024

KCC2 direct activator

OV350 IV

Phase 1 study initiation

Q1 2025

Results from Phase 1 study

Early 2026

Cleared by regulators to proceed with Phase 2, but

OV888/ GV101

pausing to assess insights from competitor trials in

Paused

CCM to inform potential approach in future

OV329

A potential best-in-class, next-generation GABA-aminotransferase inhibitor

Validated target: Inhibition of GABA-aminotransferase (GABA-AT)

Therapeutic index: OV329 seeks to avert the ocular toxicity of vigabatrin

Unique pharmacokinetic/pharmacodynamic profile: Low doses with prolonged effect

Potential portfolio in a product: Multiple indications in which neuronal hyperexcitability is implicated

1. Yang J, et al. Vigabatrin-induced retinal toxicity is partially mediated by signaling in rod and cone photoreceptors. PLoS One. 2012;7(8):e43889. doi: 10.1371/journal.pone.0043889. Epub 2012 Aug 30.

A next-generation GABA-AT targeting improved safety & tolerability

OV329 seeks to improve upon vigabatrin, a 1st-generation GABA-AT inhibitor

Sabril profile:

Sabril Peak Sales in U.S. with

Ocular Safety Label

~$330

MILLION

(Not representative of global sales)4

Disclaimer

Ovid Therapeutics Inc. published this content on November 12, 2024, and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on November 12, 2024 at 13:50:05.415.